Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2315497 +/- Darolutamide in mCRPC
NCT03724747Phase 1Completed
- Sponsor
- Bayer
- Start
- Dec 2018
- Primary completion
- Aug 2022
- Modality
- Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies, Peptide-Drug Conjugates
- Countries
- 3
01
Overview
Phase 1, open-label trial of pelgifatamab corixetan in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Bayer. Primary endpoints: Maximum tolerated dose (MTD) of BAY2315497 injection and Maximum tolerated dose (MTD) of BAY2315497 injection in combination with darolutamide. Started Dec 2018; status: completed.
02
Drugs
pelgifatamab corixetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03724747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724747.